OTIC FILE CUPY





US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE ABERDEEN PROVING GROUND, MARYLAND 21010-5425

USAMRICD-TR-87-02



AD-A183 739

EFFECTS OF CHRONIC PYRIDOSTIGMINE ADMINISTRATION ON SUSTAINED WORK OUTPUT IN MONKEYS

DAVID M. PENETAR

JUNE 1987



DISTRIBUTION STATEMENT A. APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED

US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND FORT DETRICK, MARYLAND 21701-5012

REPORT DOCUMENTATION PAGE Set Sum Approved for Approved App	UNCLASSIFIED SECURITY CLASSIFICATION OF THIS PAGE		A	D-AI	8373	39	
In REPORT SIGURITY CASSIFICATION I/A JUNCLASSIFICATION AUTHONITY I/A Just Statistic Control AuthONITY A Just Statistic Control AuthONITY B Just Statistic Control AuthONITY B <td< th=""><th>REPORT D</th><th>OCUMENTATIO</th><th>N PAGE</th><th></th><th>OMBN</th><th>0 0704-0188</th></td<>	REPORT D	OCUMENTATIO	N PAGE		OMBN	0 0704-0188	
Sz. SECURTY CLASSIFICATION AUTHORY S. DESTRUCTION/AUALABLERY OF REPORT MA Approved for public release; distribution unlimited APR PALASSIFICATION/DOWNGRADING SCHEDULE Approved for public release; distribution unlimited A. PERFORMING CREANZATION REPORT NUMBER(S) S. MONTORNG ORGANIZATION REPORT NUMBER(S) USAMR ICD-TR-87-02 USAMR ICD-TR-87-02 S. NAME OF REPORTING ORGANIZATION U.S. Army Medical Research of Chemical Defense; SCRD-UV-PA S. Army Medical Research (# APProved for MonitoRong ORGANIZATION U.S. Army Medical Defense; SCRD-UV-PA GC. ADDRESS (GN; State, and 20°Code) 7b. ADDRESS (GN; State, and 20°Code) 7b. ADDRESS (GN; State, and 20°Code) Aberdeen Proving, Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 State, and 20°Code) 05 OHEC SYMBOL (# Applicable) 9 PROCUREMENT HISTRUMENT IDENTIFICATION NUMBER VORC UNIT RECENT NO. State, and 20°Code) 10 SUMEC OF FUNDING MUMBERS VORC UNIT RECENT NO. VORC UNIT RECENT NO. State Export Technical The Inter Covered Procomposition NO. 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT Technical 15 DIRECT TRANS (Contour on reverse if necestary and identify by block number) Technical for the State Covered Processing schedule, while the additistration on Sustained Work Output in Monkey, Progressive Ratio <td>1a. REPORT SECURITY CLASSIFICATION</td> <td></td> <td>16. RESTRICTIVE</td> <td>MARKINGS</td> <td></td> <td></td>	1a. REPORT SECURITY CLASSIFICATION		16. RESTRICTIVE	MARKINGS			
M/A Approved for public release; distribution unlimited PA PLACASTRATION NEPORT NUMBER() Inimited USAMR ICD-TR-87-02 USAMR ICD-TR-87-02 USAMR ICD-TR-87-02 USAMR ICD-TR-87-02 Stand OF REFORMING ORGANIZATION REPORT NUMBER() S. MONY CONCONCO ORGANIZATION U.S. Army Medical Research institute of Chemical Defense, SCRP-UV-R0 Sc. ADDRESS (GN, Stete and ZP Code) 7b. ADDRESS(GN, Stete, and ZP Code) Aberdeen Proving, Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 Aberdeen Proving, Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 B. DARG OF RUNDING FORMONING (M Applicable) 2. PROCUREMENT NUTRUMENT UDINTEGATION NUMBER RE. ADDRESS (CN, State, and ZP Code) 10 SOURCE OF FUNDING NUMBERS RE. ADDRESS (CN, State, and ZP Code) 10 SOURCE OF FUNDING NUMBERS RESONAL AUTHORG) Penetar, D.N. (Ph. D)* The Containe Strange of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12 PERSONAL AUTHORG) Panet Overse in Accession an Operant schedule requiring large amounts of sustained work. One monkey of edict Igmine, Nonkey, Progressive Ratio 13 TOPE OF RIPORT 13b THME COVERED 14 DATE OF REPORT (Yest Month, Day) 15 PAGE COUNT 14 DATE OF REPORT (Cortinue on revers in Accessin an Operant schedule requiring large amounts of sust							
Display Display <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
USAME ICD-TR-87-02 USAME OF PREFORMING ORGANIZATION U.S. ARMS OF PREFORMING ORGANIZATION U.S. ARMS OF PREFORMING ORGANIZATION U.S. ARMS OF MONTORING ORGANIZATION OF Chemical Defense USAME OF PREFORMING ORGANIZATION U.S. ARMS OF MONTORING ORGANIZATION OF Chemical Defense OF Chemical Defense DEFENSION AUTHORS: Penetar, D.M. (Ph.D)* Is TIME CoveRED Is DIME CoveRED </td <td colspan="2">26. DECLASSIFICATION/DOWNGRADING SCHEDULE</td> <td></td> <td>r public re.</td> <td>lease; disti</td> <td>lDution</td>	26. DECLASSIFICATION/DOWNGRADING SCHEDULE			r public re.	lease; disti	lDution	
Sea NAME OF REPORMING ORGANIZATION U.S. ATMY Medical Research of Chemical Defense School (M AppReview) School School Chemical Defense School (School Chemical Defense, SChO-UU-R) 6c. ADDRESS (Gy, State, and ZP Code) 7b. ADDRESS (Gy, State, and ZP Code) 7b. ADDRESS (Gy, State, and ZP Code) Aberdeen Proving, Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 Aberdeen Proving, Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 Ba. MAME OF FUNDING/SPONSORING ORGANIZATION BB. OFFICE SYMBOL (M AppRevalue) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER BE: ADDRESS (Gy, State, and ZP Code) BD. OFFICE SYMBOL (M AppRevalue) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER BE: ADDRESS (Gy, State, and ZP Code) BD. OFFICE SYMBOL (M AppRevalue) 10. SOURCE OF FUNDING NUMBERS BE: ADDRESS (GY, State, and ZP Code) ID. SOURCE OF FUNDING NUMBERS ID. SOURCE OF FUNDING NUMBERS BE: ADDRESS (GY, State, and ZP Code) ID. SOURCE OF FUNDING NUMBERS ID. SOURCE OF FUNDING NUMBERS BE: ADDRESS (GY, State, and ZP Code) ID. SOURCE OF FUNDING NUMBERS ID. SOURCE OF FUNDING NUMBERS BE: ADDRESS (GY, State, and ZP Code) ID. SOURCE OF FUNDING NUMBERS ID. SOURCE OF FUNDING NUMBERS BE: ADDRESS (GY, State, and ZP Code)	4. PERFORMING ORGANIZATION REPORT NUMBER(S)		5. MONITORING C	ORGANIZATION RE	PORT NUMBER(S)	,	
U.S. Army Medical Research of (# applicable) U.S. Army Medical Research Institute of SGRD-UV-DA Of Chemical Defense SGRD-UV-DA Chemical Defense, SGRD-UV-PO 6c. ADDRESS (GN, State, and ZP Code) 7b. ADDRESS (GN, State, and ZP Code) 7b. ADDRESS (GN, State, and ZP Code) 8c. ADDRESS (GN, State, and ZP Code) 8b. OFFICE SYMBOL Aberdeen Proving Ground, MD 21010-5425 8c. ADDRESS (GN, State, and ZP Code) 8b. OFFICE SYMBOL 9. PROCUREMENT MISTRUMENT IDENTIFICATION NUMBER 8c. ADDRESS (GN, State, and ZP Code) 8b. OFFICE SYMBOL 9. PROCUREMENT MISTRUMENT IDENTIFICATION NUMBER 8c. ADDRESS (GN, State, and ZP Code) 10. SOURCE OF TUMDING NUMBERS Not State 213 8c. ADDRESS (GN, State, and ZP Code) 10. SOURCE OF TUMDING NUMBERS Not State 213 11. TITLE (Include Seconity Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PRESONAL AUTHORS) Penetar, D.M. (Ph. D.)* 14 DATE OF REPORT (Vear, Month, Day) 15 PAGE COUNT Technical Term of June Covered 16. SUPFICHENTARY NOTATION 13b. TIME COVERED 14 DATE OF REPORT (Vear, Month, Day) 15 PAGE COUNT Technical Contine on reverse d necessary and identify by block number) 17. COIATI CODES 13b. SUBECT TERMS (Continue on reverse d necessary and identify by block numb	USAMRICD-TR-87-02		USAMRICD-T	R-87-02			
of Chemical Defense SGRD-UV-DA Chemical Defense, SGRL-UV-RC 6C. ADDRESS (GR, State, and ZPCode) 7b. ADDRESS (GR, State, and ZPCode) 7b. ADDRESS (GR, State, and ZPCode) Aberdeen Proving, Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 Es. NAME OF FUNCING/SPONSORING ORGANIZATION Bb. OFFCE SYMBOL (# opplicable) 9. PROLUREMENT INSTRUMENT IDENTFICATION NUMBER 82. ADDRESS (GR, State, and ZPCode) 10. SOURCE OF FUNDING NUMBERS WORK UNIT ACCESSION NO 62734A 875 AA 11. TITLE (Include Security Class/Ketton) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PERSONAL AUTHOR(S) Penetar, D.M. (PL.D)* 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 19 13. TYPE OF REFORT 13b. TIME COURED FROM 6 JUL 79 TO JUL 81 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 19 13. TYPE OF REFORT 13b. TIME COURED FROM 6 JUL 79 TO JUL 81 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 19 13b. TYPE OF REFORT 13b. TIME COURED FROM 6 JUL 79 TO JUL 81 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 19 13b. TYPE OF REFORT 13b. TIME COURED FROM 6 JUL 79 TO JUL 81 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 19 13b. TYPE OF REFORT 1							
6c. ADDRESS (GN, State, and ZP Code) 7b. ADDRESS (GN, State, and ZP Code) 7b. ADDRESS (GN, State, and ZP Code) 7b. ADDRESS (GN, State, and ZP Code) 8a. NAME OF FUNDING/SPONSORING 8b. OFFICE SYMBOL (If applicable) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER 8c. ADDRESS (GN, State, and ZP Code) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Image: State and ZP Code) 8c. ADDRESS (GN, State, and ZP Code) 10. SOURCE OF TUNDING NUMBERS Image: State and ZP Code) 8c. ADDRESS (GN, State, and ZP Code) 10. SOURCE OF TUNDING NUMBERS Image: State and ZP Code) 8c. ADDRESS (GN, State, and ZP Code) 10. SOURCE OF TUNDING NUMBERS Image: State and ZP Code) 8c. ADDRESS (GN, State, and ZP Code) 10. SUPECH TENSITY COMPANDERS Image: State and ZP Code) 11. THLE (Include Secondy Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PRENONAL AUTHORS) Penetar, D.M. (Ph.D)* 11a DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT Technical 13. THF OF REPORT 13b. THME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT Technical 19 14. SUPECH TERMS (Continue on reverse if necessary and identify by Block number) 19 19 19 15. SUPECH MEMARY NOTADA 10. (Jo. (Jo. (Jo. (• • • • • • • • • • • • • • • • • • •					ite of	
Aberdeen Proving Ground, MD 21010-5425 Aberdeen Proving Ground, MD 21010-5425 B3. NAME OF FUNCING/SPONSORING ORGANIZATION Bb. OFFICE SYMBOL (If applicable) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER SPORTAM B2. ADDRESS (Cry. State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS PROGRAM PROLECT TASK NO. WORV.UNIT ACCESSION NO 213 B2. ADDRESS (Cry. State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS PROGRAM PROLECT TASK NO. WORV.UNIT ACCESSION NO 213 B3. TAPE OF REPORT Table State Administration on Sustained Work Output in Monkeys (U) 12. PRESONAL AUTHORS) Penetar, D.M. (Ph.D)* 14 DATE OF REPORT (Vear. Month, Day) 15. PAGE COUNT Technical 15. PAGE COUNT Provides State Address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 17. COLATL CODES Fill O 18 SUBECT TERMS (Continue on reverse if necessary and identify by block number) File of GROUP Sub-GROUP Pyridestigmine, Monkey, Progressive Ratio 19. SUB-GROUP 18 SUBECT TERMS (Continue on reverse if necessary and identify by block number) File of GROUP Sub-GROUP 18 SUBECT TERMS (Continue on reverse if necessary and identify by block number) 19. SUB-GROUP 19. SUB-GROUP 19. SUB-GROUP 10. 10. 19. SUB-GROUP		SGRD-UV-DA					
Ba. NAME OF FUNCING/SPONSORING ORGANIZATION Bb. OFFICE SYMBOL (# applicable) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Bc. ADDRESS (Cny, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS 10. SOURCE OF FUNDING NUMBERS Bc. ADDRESS (Cny, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS 213 11. TITLE (Include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PERSONAL AUTHORS) Penetar, D.M. (Ph.D)* 13. NFG OF REPORT 13b TIME COVERED 14. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 10 116 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *KiD GROUP 19 16 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *Profication on reverse if necessary and identify by block number) *More pails of cynomolgues monkeys using test tested with repeated chronic pyridostigmine administration of the pair earned its rewards on a persant s	6c. ADDRESS (City, State, and ZIP Code)		7b. ADDRESS (City	y, State, and ZIP (iode)		
Ba. NAME OF FUNCING/SPONSORING ORGANIZATION Bb. OFFICE SYMBOL (# applicable) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Bc. ADDRESS (Cny, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS 10. SOURCE OF FUNDING NUMBERS Bc. ADDRESS (Cny, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS 213 11. TITLE (Include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PERSONAL AUTHORS) Penetar, D.M. (Ph.D)* 13. NFG OF REPORT 13b TIME COVERED 14. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 10 116 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *KiD GROUP 19 16 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *Profication on reverse if necessary and identify by block number) *More pails of cynomolgues monkeys using test tested with repeated chronic pyridostigmine administration of the pair earned its rewards on a persant s	Aberdeen Proving Ground, MD	21010-5425	Aberdeen Pr	oving Ground	1. MD 21010)-5425	
ORGANIZATION (# applicable) BE: ADDRESS (Gry, State, and ZP Code) 10 SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 62734A PROJECT NO. 62734A TASK NO. 62734A TASK NO. 62734A NO. 875 AA 213 11. TITLE (include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 875 AA 213 12. PERSONAL AUTHORS) Penetar, D.M. (Ph.D)* 14 DATE OF REPORT (ver, Month, Day) 15 PAGE COUNT Technical 13. TITE (include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 15 PAGE COUNT Technical 13. TYPE OF REPORT Technical 13b TIME COVERED For 6 JUL 2910 Jul 81 14 DATE OF REPORT (ver, Month, Day) 15 PAGE COUNT 19 14. DATE OF REPORT (ver, Month, Day) 15 PAGE COUNT Technical 18 DUB/ECT TERMS (Continue on reverse if necessary and identify by block number) 7 COIAH CODES 10 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 7 FRUD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 7 FRUD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 7 FRUD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 7		8b. OFFICE SYMBOL					
PROJECT TASK NO WORK UNIT ACCESSION NO 11 TITLE (Include Security Classification) BT162734A BT162734A BT162734A BT162734A BT162734A BT162734A BT162734A DT17 11 TITLE (Include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12 PERSONAL AUTHORS; Penetars, D.M. (Ph.D)* 13a. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13b. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13a. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13c. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13c. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13c. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13c. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13c. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT		(If applicable)					
ELÉMENT NO. NO. ACCESSION NO 62734A 3M162734A 875 AA 213 11. TITLE (Include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PERSONAL AUTHOR(5) Penetar, D.M. (Ph.D)* 13a. TYPE OF REPORT 15 TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 13b. TYPE OF REPORT 15 TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 17. Technical FROM 6 Jul 7910 Jul 81 June 1987 19 16. SUBPLEMENTARY NOTATION **Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 18 SUBJECT TERMS (Continue on reverse if necestary and identify by block number) Prido group SUBJECT TERMS (Continue on reverse if necestary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 10. 15. 19 14 OATE OF Commol gue monkeys userse tested with repeated chronic pyridostigmine administration to assess this drug's offects on an operant schedule requiring large amounts of sustained work. One monkey of each pair earned reinforcement on a progressive ratio lever- 17. Subject (Continue on several hours, whereas the progressive interval schedule produced a high rate of responding. Terestart on three weeks at a time. The resound of responding. 19.	8:. ADDRESS (City, State, and ZIP Code)		10. SOURCE OF F	UNDING NUMBER	S		
62734A 3M162734A 875 AA 213 11. TITLE (Include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. FERSONAL AUTHOR(5) Penetar, D.M. (Ph.D)* 13a. TYPE OF REPORT 13b TIME COVERED 14 DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT 15. SUPPLEMENTARY NOTATION ************************************					TASK		
11. TITLE (Include Security Classification) Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PERSONAL AUTHOR(S) Penetar, D.M. (Ph.D)* 13. TYPE OF REPORT 13b TIME COVERED 14. DATE OF REPORT (Vew, Month, Day) 15 PAGE COUNT 15. TYPE OF REPORT 13b TIME COVERED 16. SUPPLEMENTARY NOTATION 14 DATE OF REPORT (Vew, Month, Day) *Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 14 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD GROUP SUBJECT TERMS (Continue on reverse if necessary and identify by block number) *FELD <td></td> <td></td> <td></td> <td></td> <td>V V</td> <td></td>					V V		
Effects of Chronic Pyridostigmine Administration on Sustained Work Output in Monkeys (U) 12. PERSONAL AUTHOR(5) Penetar, D.M. (Ph.D)* 13. TYPE OF REPORT 14. DATE OF REPORT 15. SUPPLEMENTARY NOTATION "CUTTENT address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 10. 10. 13. TO COSATI CODES 19. ABSTRACT (Continue on reverse if necessary and identify by block number) PYridostigmine, Monkey of each pair earned 19. ABSTRACT (Continue on reverse if necessary and identify by block number)			02734A	5M162734A	875 AA	213	
Penetar, D.M. (Ph.D)* 13a. TYPE OF REPORT Technical 14 DATE OF REPORT (Year, Month, Day) 15. SUPPLEMENTARY NOTATION **Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 17. COSAIL CODE (10. 19 10 IB SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 10 15. 10. 19 11. OS IO 11. 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 10 15. 13. 15. 13. 13. 14. 14. 15. GROUP 16. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio Pyridostigmine admini- 16. 15. 17. Osea Control of control of reverse if necessary and identify by block number) Pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The	Effects of Chronic Pyridostig	nine Administrat	ion on Susta	ined Work Ou	tput in Mor	ıkeys (U)	
Technical FROM 6 Jul 79TO Jul 81 June 1987 19 16. SUPPLEMENTARY NOTATION "Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 17 COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 17 COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 17 COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 19 06 15 19 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 19 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey of each pair earned the requiring large amounts of sustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The progressive interval schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slour rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whele blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration o	Penetar, D.M. (Ph.D)*						
 16. SUPPLEMENTARY NOTATION **Current address is Neuropsychiatry Division, Walter Reed Army Institute of Research, Washington, D.C. 17. COSATLCODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 06. 15. 10. 06. 15. 10. 06. 15. 10. 11. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 13. ASTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 13. ASTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey of each pair earned chronic pyridostigmine administration to assess this drug's effects on an operant schedule requiring large amounts of sustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The progressive ratio schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce while blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 perineution/AvaiLABULTY OF ABSTRACT 21 ABSTRACT SECURITY				RT (Year, Month,)			
17. COSATI CODES 18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) FIELD GROUP SUB-GROUP 10 10 Pyridostigmine, Monkey, Progressive Ratio 19 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 ABSTRACT (Continue on reverse if necessary and identify by block number) Pyridostigmine, Monkey, Progressive Ratio 9 asstration to assess this drug's offects on an operant schedule requiring large amounts of sustained work. One monkey of eact, pair earned reinforcement on a progressive ratio lever- 9 responding, for several hours, whereas the progressive interval schedule produced steady, slou rates of r	*Current address is Neuropsychi	iatry Division,	Walter Reed	Army Institu	ite of Resea	arch,	
10 10 06 15 17 Wo pairs of cynomolgus monkeys were tested with repeated chronic pyridostigmine administration to assess this drug's effects on an operant schedule requiring large amounts of sustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The progressive ratio schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. 20 DUSTRIBUTION / AVAILABILITY OF ASSTRACT 21 ABSTRACT SECURITY CLASSIFICATION 21 DUNCLASSIFIED TOWN / AVAILABILITY OF ASSTRACT 21 ABSTRACT SECURITY CLASSIFICATION 22 NAME OF RESPONSIBLE INDIVIDUAL 21 ABSTRACT SECURITY CLASSIFICATION 22 ANAME OF RESPONSIBLE INDIVIDUAL 21 ABSTRACT SECURITY CLASSIFICATION 22 ANAME OF RESPONSIBLE INDIVIDUAL 22 SAME OF RESPONSIBLE INDIVIDUAL 22 BENER C. SOUTHWORTH, LTC, MS 21 ABSTRACT SECURITY CLASSIFICATION		18. SUBJECT TERMS (Continue on reverse	e if necessary and	identify by block	k number)	
06 15 19 ABSTRACT (Continue on reverse if necessary and identify by block number) MTwo pairs of cynomolgus monkeys usere tested with repeated chronic pyridostigmine administration to assess this drug's effects on an operant schedule requiring large amounts of sustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The progressive ratio schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. 20 ptotribution / AVAILABILITY OF ASSTRACT 21 ABSTRACT SECURITY CLASSIFICATION 21 ABSTRACT SECURITY CLASSIFICATION 22c OFFICE SYMBOL 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (include Area Code) 22c OFFICE SYMBOL 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (include Area Code) 22c OFFICE SYMBOL 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (include Area Code) 22c OFFICE SYMBOL	FIELD GROUP SUB-GROUP	Pyridostigmine	, Monkey, Pr	ogressive Ra	atio		
19 ABSTRACT (Continue on reverse if necessary and identify by block number) PTWo pairs of cynomolgus monkeys usere tested with repeated chronic pyridostigmine administration to assess this drug's offects on an operant schedule requiring large amounts of sustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The progressive ratio schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. 20 DISTRIBUTION / AVAILABILITY OF ABSTRACT 21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED/UNCLASURACT/UNCLASURACT/UNCLASSIFIED/UNCLASSIFIED/UNCLASSIFIED/U	1 05 10						
stration to assess this drug's effects on an operant schedule requiring large amounts ofsustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on aprogressive interval schedule. The progressive ratio schedule produced a high rate ofresponding for several hours, whereas the progressive interval schedule produced steady, slowrates of responding. Pyridostigmine was administered, orally, to all monkeys in doses thatreduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. Theresults indicate that the ability of the primates to maintain a high rate of behavior over anextended period of time (two to three hours) is affected by the initial administration ofchronic pyridostigmine, while the ability to maintain a lower rate of response is not.Furthermore, repeated sets of chronic pyridostigmine administration are without affect onsustained high rates of responding.20 pistribution (Availability of ABSTRACTCluncLASSIFIED/UNC MAYED22a NAME OF RESPONSIBLE INDIVIDUALGEORGE C. SOUTHWORTH, LTO, MS22a NAME OF RESPONSIBLE INDIVIDUALGEORGE C. SOUTHWORTH, LTO, MS		and identify by block (number)				
stration to assess this drug's effects on an operant schedule requiring large amounts ofsustained work. One monkey of each pair earned reinforcement on a progressive ratio lever-pressing schedule, while the second (or "yoked") member of the pair earned its rewards on aprogressive interval schedule. The progressive ratio schedule produced a high rate ofresponding for several hours, whereas the progressive interval schedule produced steady, slowrates of responding. Pyridostigmine was administered, orally, to all monkeys in doses thatreduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. Theresults indicate that the ability of the primates to maintain a high rate of behavior over anextended period of time (two to three hours) is affected by the initial administration ofchronic pyridostigmine, while the ability to maintain a lower rate of response is not.Furthermore, repeated sets of chronic pyridostigmine administration are without affect onsustained high rates of responding.20 pistribution (Availability of ABSTRACTCluncLASSIFIED/UNC MAYED22a NAME OF RESPONSIBLE INDIVIDUALGEORGE C. SOUTHWORTH, LTO, MS22a NAME OF RESPONSIBLE INDIVIDUALGEORGE C. SOUTHWORTH, LTO, MS	Two pairs of cynomolgus monkeys	s were tested wi	th repeated	chronic pyr:	ldostigmine	admini-	
pressing schedule, while the second (or "yoked") member of the pair earned its rewards on a progressive interval schedule. The progressive ratio schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 DISTRIBUTION / AVAILABILITY OF ABSTRACT 21 ABSTRACT SECURITY CLASSIFICATION 21 OUNCLASSIFIED/UNXIMITED DAME AS RPT DILC USERS 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (Include Area Code) 22c OFFICE SYMBOL 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (Include Area Code) 22c OFFICE SYMBOL 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (Include Area Code) 22c OFFICE SYMBOL	stration to assess this drug's	effects on an o	perant sched	ule requirin	ng large amo	ounts of	
progressive interval schedule. The progressive ratio schedule produced a high rate of responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not.20 DETRIBUTION / AVAILABILITY OF ABSTRACT21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED20 DETRIBUTION / AVAILABILITY OF ABSTRACT21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED20 DETRIBUTION / AVAILABILITY OF ABSTRACT21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED20 DETRIBUTION / AVAILABILITY OF ABSTRACT21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED22 A NAME OF RESPONSIBLE INDIVIDUAL GEORGE C. SOUTHWORTH, LTC, MS21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED22 DETELEPHONE (Include Area Code)22c OFFICE SYMBOL SGRD-HIV-D	sustained work. One monkey of	each pair earne	d reinforcem	ent on a pro	ogressive ra	atio lever-	
responding for several hours, whereas the progressive interval schedule produced steady, slow rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding.	pressing schedule, while the se	econd (or "yoked	") member of	the pair ea	arned its re	ewards on a	
rates of responding. Pyridostigmine was administered, orally, to all monkeys in doses that reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 DISTRIBUTION / AVAILABILITY OF ABSTRACT DUNCLASSIFIED/UALIMITED SAME AS RPT 21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED/UALIMITED SAME AS RPT 22a NAME OF RESPONSIBLE INDIVIDUAL GEORGE C. SOUTHWORTH, LTC, MS 21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED	progressive interval schedule.	The progressiv	e ratio sche	dule produce	ed a high ra	ite of	
reduce whole blood cholinesterase levels 30% to 54% for one to three weeks at a time. The results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 DISTRIBUTION / AVAILABILITY OF ABSTRACT 21 ABSTRACT SECURITY CLASSIFICATION 22 DISTRIBUTION / AVAILABILITY OF ABSTRACT 23 NAME OF RESPONSIBLE INDIVIDUAL 24 NAME OF RESPONSIBLE INDIVIDUAL 25 TELEPHONE (Include Area Code) 22 DISTRIBUTION / AVAILABILITY OF, MS	rates of responding Puridents	vnereas the prog	ressive inte	rval schedul	le produced	steady, slow	
results indicate that the ability of the primates to maintain a high rate of behavior over an extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 pistribution / Availability of ABSTRACT DunctAssifieD/UNCHAILABILITY OF ABSTRACT DunctAssifieD/UNCHAILABILITY OF ABSTRACT 21 ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED/UNCHAILABILITY OF ABSTRACT 22a NAME OF RESPONSIBLE INDIVIDUAL GEORGE C. SOUTHWORTH, LTO, MS	reduce whole blood cholinester	ignifie was admin	15 tered, ora	lly, to all	monkeys in	doses that	
extended period of time (two to three hours) is affected by the initial administration of chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 Distribution / Availability OF ABSTRACT CluncLASSIFIED/UN: MITED SAME AS RPT 22a NAME OF RESPONSIBLE INDIVIDUAL GEORGE C. SOUTHWORTH, LTC, MS 21 ABSTRACT SECURITY CLASSIFICATION	results indicate that the abilities	ity of the prima	tes to maint	ain a high i	rate of hehe	vior over a	
chronic pyridostigmine, while the ability to maintain a lower rate of response is not. Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 Distribution / Availability of Abstract CluncLassifieD/UN: Mited Same as RPT 22a NAME OF RESPONSIBLE INDIVIDUAL GEORGE C. SOUTHWORTH, LTO, MS	extended period of time (two to	three hours) i	s affected b	v the initia	al administr	ration of	
Furthermore, repeated sets of chronic pyridostigmine administration are without affect on sustained high rates of responding. 20 Distribution / Availability of Abstract 21 Abstract Security Classification 22 Distribution / Availability of Abstract 23 NAME OF RESPONSIBLE INDIVIDUAL 22 RAME OF RESPONSIBLE INDIVIDUAL 22 George C. SOUTHWORTH, LTC, MS	chronic pyridostigmine, while	the ability to m	aintain a lo	wer rate of	response is	s not.	
20 Distribution / Availability of abstract 21 Abstract security classification 20 Distribution / Availability of abstract 21 Abstract security classification 20 Distribution / Availability of abstract 21 Abstract security classification 20 Distribution / Availability of abstract 21 Abstract security classification 20 Distribution / Availability of abstract 21 Abstract security classification 21 Distribution / Availability of abstract 21 Abstract security classification 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TelePHONE (Include Area Code) 22c Office sy MBOL GEORGE C. SOUTHWORTH, LTO, MS (301) 671-4442 SGRD-HV-D	Furthermore, repeated sets of a	Furthermore, repeated sets of chronic pyridostigmine administration are without affect on					
DUNCLASSIFIED/UNTED SAME AS RPT DTIC USERS UNCLASSIFIED 22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (Include Area Code) 22c OFFICE SYMBOL GEORGE C. SOUTHWORTH, LTO, MS (301) 671-4442 SGRD-IIV-D	sustained high rates of respond	ling. 🧀 🗠	-				
22a NAME OF RESPONSIBLE INDIVIDUAL 22b TELEPHONE (Include Area Code) 22c OFFICE SYMBOL GEORGE C. SOUTHWORTH, LTO, MS (301) 671-4442 SGRD-IIV-D				CURITY CLASSIFIC	ATION		
GEORGE C. SOUTHWORTH, LTC, MS (301) 671-4442 SGRD-HV-D		RPT DTIC USERS			ALZZ OFFICE FY	(MRO)	
		PR edition may be used u	الالالمكامل فاستكر فنفا المستاهية				

TRUCTOR ALCORATION AND A CONTRACTOR AND A C

	-	'				
All ot	her e	bitic	ons a	re o	bsol	ete

2022

Services Services

のないので、「「「

PREFACE

This work was accomplished under 875AA Pharmacology and Efficacy of Prophylactic and Therapeutic Compounds. The ICD Protocol number is 105-8-00-A-035 and the work is documented in ICD notebooks # 21-80, 38-80, and 05-82.

Acces	sion For			
NTIS	GRA&I	r X		
DTIC	TAB	- A		
Unam	ounced	ñ	ļ	
Justi	fication			
		······		
By				
Distr	ibution/			
Ava1	lability	Codes		
	Availan		-1	
Dist	Specia			
				/
A /				12
A-1	{ [\ ·
	L		ł	

state basedered

ESCALATION OF

ACKNOWLEDGMENT

The author wishes to thank William G. Lee, Gary Zimmer, and Richard Rodriguez for their assistance with the animals, and Andris Kaminskis for performing the cholinesterase assays.

iii

TABLE OF CONTENTS

PAGE

LIST OF FIGURES AND TABLES

10 H 0 H 0 H 0 H 0

.

.

.

PAGE

000

1

いたいとうない

ž

and the second first second second second second in the second second second second second second second second

FIGURE 1 - Progressive Ratio breaking points for two monkeys over no drug and drug conditions	6
FIGURE 2 - Session by session breaking points for two monkeys	7
TABLE 1 - Mean breaking points and whole blood cholinesterase activity for two monkeys under a Progressive Ratio 10 schedule of food reinforcement: Drug vs No Drug Conditions.	8
TABLE 2 - Mean number of responses and whole blood cholinesterase activity for two monkeys under a Progressive Ratio 10 schedule of food reinforcement: Drug vs No Drug Conditions	9
TABLE 3 - Progressive interval responses and responses per reinforcer for two monkeys	10

INTRODUCTION

relatively long-acting, reversible **Pyridostigmine** is а carbamate-type cholinesterase inhibitor. This drug has been proposed for use in the field as a medical pretreatment when nerve agents are a possible agent threat. This type of drug prophylaxis is based on the concept of protecting a percentage of the acetyl-cholinesterase from phosphorylation and inactivation. To be effective, protection must occur before exposure to organophosphorus nerve agents. Protection of the enzyme renders it functionally inoperative since it can no longer hydrolyze acetylcholine while in The physiological and behavioral consequences of inactivating its inhibited state. different percentages of the pool of acetylcholinesterase are under study by many laboratories and countries at the present time. As a consequence of this inhibition, changes can be expected to occur at the neuromuscular junction.

Myasthenia gravis is a neuromuscular disease characterized by weakness and marked fatigability of skeletal muscle (Drachman, 1978). Studies involving these patients have shown that neostigmine improves both voluntary muscular activity and muscular response to tetanic stimulation. An equal dose of neostigmine in nonmyasthenics, however, leads to a reduced muscular response to tetanic stimulation, which is accompanied by fasciculations, local weakness, and recurrent action potentials following a single stimulus (Grob, 1963).

Even in myasthenic patients, characteristics of the disease, such as increased weakness, decreased availability of acetylcholine receptors, reduced miniature endplate potential amplitudes, and damaged post-synaptic folds, can occur when excessive amounts of the anticholinesterase drug are prescribed (Drachman, 1978).

Given the neuromuscular effects of the carbamate class of anticholinesterase compounds, an appropriate test of their deleterious effects would be one that assesses muscular weakness or fatigability within the range of acetylcholinesterase inhibition that provides significant protection against multiple LD50 nerve agent challenges. The progressive ratio (PR) schedule of reinforcement is a method of studying relatively large numbers of responses over long-session times. On a PR schedule, reinforcement follows a fixed number of responses. This defines the response requirement. During the experimental trial period, the number of responses required to earn a reinforcement increases by a predetermined increment after each reinforcement. The response requirement continues to increase until the subject ceases to respond for a defined period of time or fails to complete the required number of responses within a given time limit. The response requirement that the subject fails to complete is termed the "breaking point." Hodos (1961) was the first investigator to report that the breaking point dependent variable is a sensitive measure of experimental manipulation. His original work revealed the sensitivity of progressive ration schedules to changes in the subject's deprivational level. Further research has extended the sensitivity of this paseline to include the increment increase in response requirement (Hodos & Kalman, 1963), duration of electrical brain stimulation (Hodos, 1965), changes in barometric pressure (Thomas, 1974), and the effects of drugs (Thompson, 1972). In the present experiment, the progressive ratio schedule was used to generate sustained levels of lever pressing. Chronic pyridostigmine was administered orally for periods up to four weeks and its effects were assessed through an analysis of the breaking point data.

いいん さんの てきからん ひょうひ ひょうしん ひんとんかい

METHODS

00000000

語どうなないである

マクシンである。それであるので

<u>Subjects</u> - Four experimentally naive, adult male cynomolgus monkeys (<u>Macaca fascicularis</u>), weighing between 4 to 6 kg, were used. The subjects were individually housed in stainless steel cages for primates (60 cm wide, 68 cm deep, 76 cm high) with continuous access to water. They were transported from the home cage to the experimental chamber individually by means of a transfer cage.

<u>Apparatus</u> - The experimental chamber was a modified home cage enclosed in a large sound-attenuated chamber located in an experimental room that was flooded with masking noise. One wall of the cage was replaced with a customized aluminum intelligence panel. The intelligence panel had three primate response levers mounted 28 cm above the grid floor. A pellet dispenser delivered a 1 gm pellet into a well that was centered below the response levers. The programming of experimental contingencies and the recording of responses were accomplished by a SCAT Behavioral Control System (Grason-Stadler Co.) and cumulative recorders (Gerbrands Co.) located in nearby rooms.

<u>Procedure</u> - Two pairs of monkeys were studied. One monkey of each pair worked on a progressive ratio 10 (PR10) schedule of food reinforcement. This schedule requires an increasing number of lever presses for each successive 1 gm food pellet reinforcer. The requirement increases by 10 each time. Thus, the subject had to complete 10 lever presses for the first reinforcer, 20 for the second, 30 for the third, etc. The value of the final completed ratio was defined as the "breaking point." In addition, a time requirement was programmed into the experiment such that the ratio had to be completed within an equivalent number of seconds (for example, a ratio of 50 had to be completed within 50 seconds, 200 within 200 seconds, and so on). A schedule that incorporates a time limit during which responses must be completed is called a "differential reinforcement of high rates of behavior," or DRH schedule. Thus the schedule in effect was a conjunctive PR10 DRH. This DRH contingency assured an overall rate of responding of not less than one response/second.

The availability of reinforcement for the other monkey of the pair was determined by the PR monkey earning his reinforcement. This procedure, called "yoking," allowed for the yoked monkey to earn a pellet when and only if the PR monkey completed the ratio requirement. The availability of reinforcement for the yoked monkey occurs when the PR monkey has earned its reinforcer. Reinforcement, however, is still contingent upon responding. A 10-second time limit for a response to occur was set. The yoked monkey had to respond within 10 seconds of the PR monkey's reinforcement in order to earn a pellet. Functionally, the schedule for these yoked monkeys was a Progressive Interval 10 with a 10-second limited hold (PI10 LH10). This schedule produced low but steady rates of response. The yoked animals were in separate but identical experimental chambers. No programmed cues signaling the availability of reinforcers were provided to either the PR or the PI monkeys. Yoking assured that an equal number of pellets were available to two sets of monkeys: one set was required to put out rapid, large, and increasing amounts of behavior for durations of one to three hours, whereas the second set was required to put out only small amounts of behavior at a slow, steady rate. Animals were tested during periods of chronic pyridostigmine administration for periods of one to four weeks. Animals were dosed on weekends but not tested behaviorally.

Baseline measurements of whole blood cholinesterase were made at least once in each set of baseline conditions as well as three days before and three days after the sets of dosing weeks. Additionally, cholinesterase measurements were made at least weekly while animals were on the drug. One to five milliliters of blood were drawn from a leg vein in the monkey's calf region (usually the saphenous), transferred to a test tube and kept on ice until enzymatic activity was assessed (Groff et al., 1976). <u>Drugs</u> - Pyridostigmine Bromide was made into a solution of 10 mg/ml suitable for oral administration by Mr. Pete Zvirblis, US Army Medical Research Institute of Chemical Defense. A dose of 7 mg/kg was given orally twice per day, 12 hours apart, by injecting the appropriate volume into an orange or banana and giving it to the animal to eat. In all cases, animals were observed to immediately consume the drug-impregnated fruit.

<u>Statistical Analysis</u> - Breaking point and response data were analyzed separately for each Progressive Ratio and Progressive Interval on a per monkey basis with a BMDP program (7D Analysis of Variance) and with a Newman-Kuels post-hoc testing procedure. The significance level was set a p < .05.

Prevented Coccess Providents (Coccession)

22.22 (C) (C) (C) (C) (C)

RESULTS

Pyridostigmine Effects on Progressive Ratio Behavior - Analysis of the averaged breaking point data for Monkey W (Figure 1 & Table 1) shows that, in the first two drug runs, breaking points dropped significantly lower than in all baseline conditions and than in the subsequent three drug runs. On the first drug run, breaking points dropped after the first day and remained at approximately half their predrug value for the three weeks Monkey W was dosed (Figure 2). Breaking point values recovered on the first nondrug test day, which was the third day after drug administration ceased, and remained stable for four weeks. Breaking point values recovered on the first nondrug test ceased, and remained stable for four weeks. Breaking points showed a much slower decline for the second drug run but eventually decreased to 60% of the second baseline set of values (Figure 2). This reduction was significantly different from all baseline conditions but not significantly different from the first drug run. Recovery was much slower after the second drug run, with responding not recovering until the fifth test day (seventh day after terminating drug administration). The third drug run produced a nonsignificant change in breakpoints although a downward trend is apparent. The fourth and fifth administrations produced no changes.

Analysis of the mean number of responses revealed similar results (Table 2). The number of responses in drug runs one and two was significantly lower than in all other conditions. The maximum number of responses observed under the non-dosed runs reveals that a large amount of lever pressing behavior is produced through this schedule.

The averaged breaking points for Monkey M for the no drug and drug conditions are shown in Figure 1 and Table 1. Breaking points during the first drug run increased from the first baseline, although not significantly. The second chronic administration of the drug significantly decreased breaking points and responses (Table 1 and 2). The third and fourth drug runs were without significant effects. Statistically, the first and second drug runs were significantly lower than all other conditions except the first baseline set. The breaking point data for the successive no drug and drug conditions for Monkey M are shown in Figure 2.

Whole blood cholinesterase activity (expressed as percent of baseline value) is shown in the tables. Values for Monkey W vary between 56% and 61% of control (i.e., these values are 54% and 39% inhibition levels), while values for Monkey M vary between 52% and 71% of control (i.e., these values are 48% to 29% inhibition levels). There appears to be no correlation between the degree of response reduction observed and cholinesterase depression. For both monkeys, the greatest reduction in responding/ breaking points did not correspond with those periods of greatest depression in enzymatic activity.

Pyridostigmine Effects on Progressive Interval Behavior - Data for each animal in the Progressive Interval paradigm were analyzed in two fashions: 1) the number of food pellets earned and consumed versus the number available; and 2) the number of responses subjects made per reinforcer available. This second measure was adopted because the number of reinforcers varied as the experimental conditions changed for the PR monkeys and thus the opportunity for the PI monkeys to respond changed. Both monkeys earned and consumed all the food pellets made available to them from their PR counterparts except on six occasions. Monkey S missed one pellet twice while Monkey P missed one pellet three times and two pellets once. The missed pellets occurred in the early portions of the session when, due to the short ratios and rapid responding by the PR monkeys, pellets were available with less than 10-second separations. The averaged number of responses per reinforcer differed considerably for the two PI monkeys (Table 3). Monkey S (yoked to Monkey W) averaged 11.5 responses per reinforcer for the no drug conditions and 5.4 for the drug conditions. Monkey P (voked to Monkey M), however, averaged 72.5 for the no drug conditions and 101.3 for the drug conditions. The difference between the drug and no drug conditions was not significant for either animal.

NUMBER OF STREET, STRE

Chronic pyridostigmine reduced cholinesterase activity in Monkey P to an average of 56% with a range of 47% to 73%, and in Monkey S to a average of 43% with a range 25% to 50%.

DISCUSSION

The results of this study present preliminary evidence for the following:

1. high amounts of work out-put can be reduced by the initial administrations of chronic pyridostigmine, and


2. repeated sets of chronic pyridostigmine administration are without effect on sustained work outputs.

The results indicate that the behavioral effects of chronic pyridostigmine administration need to be assessed in areas where large amounts of work are required since yoked animals working at a much reduced total work load showed no drug effects. Monkey P's response level was much higher than that of the other PI monkey (S) but still considerably less than its yoked PR monkey (M) (Tables 2 & 3). The observed drug effects are probably not related to the motivational effects of food reinforcement, nor to any gastric discomfort presumably caused by this drug. A decrease in the reinforcing efficacy of food would have resulted in decreased responding in the PR group and decreased food intake in the PI group.

The observed drug effects do not seem to be related to whole blood cholinesterase inhibition. The relationship of the behavioral effects to red blood cell cholinesterase, plasma cholinesterase, or specific regions of the central nervous system's cholinesterase inhibition remain unresolved.

Importantly, it is not the high rates of behavior but rather the ability to maintain these high rates over an extended period of time that is affected by pyridostigmine administration. Analysis of the cumulative records revealed that the progressive ratio animals responded as fast as when drugged as when not drugged. Behavioral performance was typical of ratio responding at all times (rates of two to three per second) and the animals' responses never dropped below a rate of one response/second. What was observed, however, was that the ratio animals ceased to respond after completing fewer ratio increments. Ratio monkeys worked for two to three hours under baseline conditions while working less than one hour during the first two drug administration series.

The implications of these data if verified through future experimental manipulations may have great import for the use of chronic pretreatment with a reversible inhibitor of cholinesterase like pyridostigmine. The use of such drugs and regimens may alter a soldier's ability to perform successfully in a sustained or continuous operations scenario.




÷

• •

Figure 1

Progressive Ratio breaking points (ordinate) for two monkeys over no drug (open bars) and drug (hatched bars) conditions. Bars indicate averaged breaking points plus and minus one standard deviation. Asterisks indicate significant decreases in breaking points (p < .05) from no drug condition.



んい

122100022

F300055

Ś

r)



Session by session (abscissa) breaking points (ordinate) for two monkeys. Bars along abscissa indicate drug sessions.

TABLE 1:	Mean b	preaking p	oints and	l whole	blood	cholinesterase	activity	for two
monkeys under a	Progres	ssive Ratio	o 10 sche	dule of	food r	einforcement:	Drug vs I	No Drug
Conditions.							-	-

Monkey W					Cholinesterase ¹ Activity
Condition	Means	SD	MAX	MIN	(% control)
ND	387	64	530	320	
D	209*	58	340	60	50%
ND	330	45	410	240	
D	256*	74	440	150	61%
ND	380	79	500	200	
D	354	65	430	230	60%
ND	379	43	450	280	
D	404	37	470	360	59%
ND	482	9 7	760	330	
D	403	38	450	360	46%
<u>Monkey M</u>					Cholinesterase Activity
Condition	Means	SD	MAX	MIN	(% control)
ND	225	54	370	130	
D	27 7	46	360	210	52%
ND	335	41	400	260	
D	254*	33	310	210	71%
ND	377	69	510	290	
D	351	30	390	310	59%
ND	430	44	500	350	
D	460	54	510	400	54%
ND	389	46	470	310	

*p < .05

 $^{\rm I}$ Whole blood cholinesterase activity

<u>Monkey</u> <u>W</u>					Cholinesterase ¹ Activity
Condition	Means	SD	MAX	MIN	(% control)
ND	7524	2587	13,780	5130	
D	2243*	1161	5,610	159	50%
ND	5386	1435	8,200	2821	
D	3453*	2113	9,460	1050	61%
ND	7325	2725	12,251	1900	
D	6264	2141	9,0 30	2534	60%
ND	7051	1 566	9,700	4060	
D	8036	1505	10,810	6303	59%
ND	11818	5326	28,856	5280	
D	7975	1511	9,907	6306	46%
<u>Monkey M</u>					Cholinesterase Activity
Condition	Means	SD	MAX	MIN	(% control)

6,877

6,301

7,800

4,650

12,750

7,410

12,250

12,751

10,810

789

2115

3250

2100

4060

4650

630

7800

5280

52%

71%

59%

54%

TABLE 2: Mean number of responses and whole blood cholinesterase activity for two monkeys under a Progressive Ratio 10 schedule of food reinforcement: Drug vs No Drug Conditions.

*p	<	.05
----	---	-----

ND

ND

ND

D

D

ND

D

ND

D

 i Whole blood cholinesterase activity

2592

3823

5542

3140*

7133

6054

8869

10458

7589

1329

1321

1330

833

2746

1015

2624

2420

TABLE 3: Progressive interval responses and responses per reinforcer for two monkeys.

		Responses	Responses	per Reinforcer
Monkey S	ND	316 <u>+</u> 190	11.8	<u>+</u> 30
	D	194 <u>+</u> 90	5.4	<u>+</u> 3
Monkey P	ND	2621 <u>+</u> 1249	72.5	<u>+</u> 35
	D	3114 <u>+</u> 1179	101.3	<u>+</u> 34

REFERENCES

Drachman DB (1978) Myasthenia Gravis (Part 2). NE J Med, 298:186-193.

Grob D (1963) Anticholinesterase intoxication in man and its treatment. In: Handbuch der Experimentellen Pharmakologie. Cholinesterases and Anticholinesterases. (ed. GB Koelle) Springer-Verlag, Berlin, pp 989-1027.

Groff WA, Kaminskis A and Ellin RI (1976) Interconversion of cholinesterase enzyme activity units by the manual delta-ph method and a recommended automated method. Clinical Toxicol, 9:353-358.

Hodos W (1961) Progressive ratio as a measure of reward strength. Science, 134:943-944.

Hodos W (1965) Motivational properties of long durations of rewarding brain stimulation. J Comp Physiol Psychol, 59:219-224.

Hodos W and Kalman G (1963) Effects of increment size and reinforcer volume on progressive ratio performance. J Exp Anal Behav, 6:387-392.

Thomas JR (1974) Changes in progressive ratio performance under increased pressures of air. J Exp Anal Behav, 21:553-562.

Thompson DM (1972) Enhancement of progressive ratio performance by chlordiazepoxide and phenobarbital. J Exp Anal Behav, 17:287-292.

DISTRIBUTION LIST

Names	Copies	Names	Copies
Defense Technical Information C ATTN: DTIC-DDAC Cameron Station, Bldg 5 Alexandria, VA 22314-6145	tr 12	Commandant US Army Chemical School ATTN: ATZN-CM-C Fort McClellan, AL 36205	1
Commander US Army Medical Research and Development Command Fort Detrick, MD 21701-5012	2	Director Armed Forces Medical Intelligence Center Fort Detrick, MD 21701-500	1
Director Walter Reed Army Institute of Research Bldg 40 Washington, DC 20307-5100	1	Commander US Army Institute of Dental Research Bldg 40 Washington, DC 20307-5100	1
Commander Letterman Army Institute of Research Bldg 1110 Presidio of San Francisco, CA	1 94129-6800	Commander US Army Institute of Surgic Research Bldg 2653 Fort Sam Houston, TX 78234	
Commander US Army Aeromedical Research Laboratory ATTN: Scientific Information Co P.O. Box 577 Fort Rucker, AL 36362-5000	l enter	Commandant Academy of Health Sciences US Army ATTN: HSHA-CDC HSHA-CDM Fort Sam Houston, TX 78234	2 -6100
Commander US Army Medical Bioengineering Research and Development Lab Bldg 568 Fort Detrick, MD 21701~5010	1	Department of Health & Human Services National Institute of Healt National Library of Medicine Bethesda, MD 20209	h
Commander US Army Medical Research Institu of Infectious Disease Bldg 1425 Fort Detrick, MD 21701-5011	1 ute	Executive Officer Naval Medical Research Inst: Naval Medical Command National Capital Region Bethesda, MD 20814	l Ítute
Commander US Army Research Institute of Environmental Medicine Bldg 42 Natick, MA 01760-5007	1	USAF School of Aerospace Medicine/VN Crew Technology Division Brooks AFB, TX 78235-5000	1

Ŋ

ŝ

Commander US Army Training and Doctrine Command ATTN: ATMD Fort Monroe, VA 23651-5000

Commander US Army Nuclear and Chemical Agency 7500 Backlick Road Bldg 2073 Springfield, VA 22150-3198

Biological Science Division Office of Naval Research Arlington, VA 22217

Mr Thomas R. Dashiell Director, Environmental & Life Sciences Office of Under Secretary of Defense Research & Engineering The Pentagon Washington, DC 20301-3080

US Army Research Office ATTN: Chem & Bio Sci Div P.O. Box 12211 Research Triangle Park, NC 27709--2211 Commander 1 US Army Chemical Research, Development & Engineering Center ATTN: SMCCR-MIS Aberdeen Proving Ground, MD 21010-5423 AFOSR/NL 1 Bldg 410, Rm A217 Bolling AFB, DC 20332

1

1

HQDA(DASG-HCD) Washington, DC 20310

Commander 27 USAMRICD ATTN: SGRD-UV-ZA SGRD-UV-ZB SGRD-UV-ZS (2 copies) SGRD-UV-RO (18 copies) SGRD-UV-AI SGRD-UV-D SGRD-UV-P SGRD-UV-V SGRD-UV-Y Aberdeen Proving Ground, MD 21010-5425

14

1

1

1